More than 350,000 people die every year from HCV-related liver diseases

From Chemistry to Cures

Non-alcoholic steatohepatitis (NASH), is one of the leading causes
of cirrhosis in adults in the United States. Approximately 9-15 million
adults in the U.S. are estimated to have NASH.

From Chemistry to Cures

An estimated 150 million people worldwide are chronically infected with HCV

From Chemistry to Cures

The CDC estimated approximately 3.2 million people
in the U.S. are chronically infected with HCV

From Chemistry to Cures

ABOUT ENANTA

We are a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Learn more about us.

Our Vision

Our primary objective is to become a leader in the field of viral infections and liver diseases.

Our Research

Enanta’s research and development is currently focused on four disease areas: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV). Learn more.